HC Wainwright & Co. Maintains Buy on Oruka Therapeutics, Raises Price Target to $70
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $40 to $70.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $40 to $70.